Lead Prodrug Candidate Is Being Developed for Chronic Neuropathic Pain SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/23/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/22/13 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K.

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/03/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre for

Novel Human Stem Cell-Based Bioassay Based on VistaGen's Human Clinical Trials in a Test Tube(TM) Platform SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/13/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue,

Company Also Completes Long-Term Debt Restructuring SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/06/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/14/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, today issued the following letter to its stockholders and the investment community from its CEO, Shawn Singh.

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, has secured a new United States patent covering the company's proprietary methods used to measure and type the toxic

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/16/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has licensed breakthrough stem cell culture technology from the McEwen Centre for Regenerative

Goal to Combine Human Stem Cell-Derived Cardiomyocytes With Novel High-Speed Kinetic Imaging SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/21/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, and

Goal to Expand VistaGen's Drug Rescue Capabilities Focused on Heart Toxicity SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/05/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, and Duke University, one of the